BANNOCKBURN, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter 2023 Financial Highlights
- Net revenue of $1,124.4 million, up 9.5% compared to $1,027.2 million in the fourth quarter of 2022
- Gross profit of $247.1 million, or 22.0% of revenue, up 6.9% compared to $231.1 million, or 22.5% of revenue, in the fourth quarter of 2022
- Net income of $57.2 million, or $0.32 earnings per share, inclusive of the impact from non-operating income, compared to net income of $47.5 million, or $0.26 earnings per share in the fourth quarter of 2022
- Adjusted EBITDA of $111.6 million, up 18.4% compared to $94.3 million in the fourth quarter of 2022
- Cash flow from operations of $51.0 million, and cash balances of $343.8 million at the end of the fourth quarter
- The Company announced that it fulfilled $250 million in share repurchases and the Board of Directors authorized an additional $250 million share repurchase authorization
Full Year 2023 Financial Highlights
- Net revenue of $4,302.3 million, up 9.1% compared to $3,944.7 million in full year 2022
- Gross profit of $981.2 million, or 22.8% of revenue, up 13.2% compared to $866.9 million, or 22.0% of revenue, in full year 2022
- Net income of $267.1 million, or $1.48 diluted earnings per share, compared to net income of $150.6 million, or $0.83 earnings per share, in full year 2022
- Adjusted EBITDA of $425.2 million, up 24.0% compared to $342.9 million in full year 2022
- Cash flow from operations of $371.3 million, up 38.8% compared to $267.5 million in full year 2022
John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team delivered strong financial results in the fourth quarter and full year of 2023 and continued to execute on our commitment to clinical excellence by providing extraordinary patient care through our resilient national platform. The patient is at the center of everything we do, and I am excited to build on this momentum in 2024 to further our mission to provide innovative services that improve outcomes, reduce costs, and deliver hope for patients and families.”
Full Year 2024 Financial Guidance
For the full year 2024, Option Care Health expects to deliver the following financial results:
- Net revenue of $4.6 billion to $4.8 billion
- Adjusted EBITDA of $425 million to $450 million
- Cash flow from operations of at least $300 million
Additionally, the Company anticipates an effective tax rate of 26% – 28% and net interest expense of approximately $55 million to $60 million.
Conference Call
Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members, including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at OptionCareHealth.com.
Investor Contacts
| Mike Shapiro | Bob East, Asher Dewhurst, Jordan Kohnstam |
| Chief Financial Officer | Westwicke |
| T: (312) 940-2538 | T: (413) 213-0500 |
| mike.shapiro@optioncare.com | optioncarehealth@westwicke.com |
Forward-Looking Statements – Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company’s definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
| December 31, | |||||
| 2023 | 2022 | ||||
| ASSETS | |||||
| CURRENT ASSETS: | |||||
| Cash and cash equivalents | $ | 343,849 | $ | 294,186 | |
| Accounts receivable, net | 377,658 | 377,542 | |||
| Inventories | 274,004 | 224,281 | |||
| Prepaid expenses and other current assets | 98,744 | 98,330 | |||
| Total current assets | 1,094,255 | 994,339 | |||
| NONCURRENT ASSETS: | |||||
| Property and equipment, net | 120,630 | 108,321 | |||
| Intangible assets, net | 20,092 | 22,371 | |||
| Referral sources, net | 315,304 | 341,744 | |||
| Goodwill | 1,540,246 | 1,533,424 | |||
| Other noncurrent assets | 126,508 | 112,737 | |||
| Total noncurrent assets | 2,122,780 | 2,118,597 | |||
| TOTAL ASSETS | $ | 3,217,035 | $ | 3,112,936 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| CURRENT LIABILITIES: | |||||
| Accounts payable | $ | 426,513 | $ | 378,763 | |
| Other current liabilities | 191,796 | 186,588 | |||
| Total current liabilities | 618,309 | 565,351 | |||
| NONCURRENT LIABILITIES: | |||||
| Long-term debt, net of discount, deferred financing costs and current portion | 1,056,650 | 1,058,204 | |||
| Other noncurrent liabilities | 120,404 | 103,278 | |||
| Total noncurrent liabilities | 1,177,054 | 1,161,482 | |||
| Total liabilities | 1,795,363 | 1,726,833 | |||
| STOCKHOLDERS’ EQUITY | 1,421,672 | 1,386,103 | |||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,217,035 | $ | 3,112,936 | |
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| NET REVENUE | $ | 1,124,390 | $ | 1,027,213 | $ | 4,302,324 | $ | 3,944,735 | |||||||
| COST OF REVENUE | 877,267 | 796,132 | 3,321,101 | 3,077,817 | |||||||||||
| GROSS PROFIT | 247,123 | 231,081 | 981,223 | 866,918 | |||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||
| Selling, general and administrative expenses | 147,783 | 148,351 | 607,427 | 566,122 | |||||||||||
| Depreciation and amortization expense | 14,784 | 14,538 | 59,201 | 60,565 | |||||||||||
| Total operating expenses | 162,567 | 162,889 | 666,628 | 626,687 | |||||||||||
| OPERATING INCOME | 84,556 | 68,192 | 314,595 | 240,231 | |||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||
| Interest expense, net | (12,432 | ) | (14,798 | ) | (51,248 | ) | (53,806 | ) | |||||||
| Other, net | 6,801 | 11,387 | 95,395 | 19,343 | |||||||||||
| Total other (expense) income | (5,631 | ) | (3,411 | ) | 44,147 | (34,463 | ) | ||||||||
| INCOME BEFORE INCOME TAXES | 78,925 | 64,781 | 358,742 | 205,768 | |||||||||||
| INCOME TAX EXPENSE | 21,748 | 17,252 | 91,652 | 55,212 | |||||||||||
| NET INCOME | $ | 57,177 | $ | 47,529 | $ | 267,090 | $ | 150,556 | |||||||
| Earnings per share, basic | $ | 0.32 | $ | 0.26 | $ | 1.49 | $ | 0.83 | |||||||
| Earnings per share, diluted | $ | 0.32 | $ | 0.26 | $ | 1.48 | $ | 0.83 | |||||||
| Weighted average common shares outstanding, basic | 176,055 | 181,925 | 178,973 | 181,105 | |||||||||||
| Weighted average common shares outstanding, diluted | 177,743 | 183,086 | 180,375 | 182,075 | |||||||||||
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
| Year Ended December 31, |
|||||||
| 2023 | 2022 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
| Net income | $ | 267,090 | $ | 150,556 | |||
| Adjustments to reconcile net income to net cash provided by operations: | |||||||
| Depreciation and amortization expense | 62,200 | 65,434 | |||||
| Deferred income taxes – net | 12,766 | 49,187 | |||||
| Other non-cash adjustments | 50,684 | 32,147 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | 224 | (36,889 | ) | ||||
| Inventories | (51,000 | ) | (41,010 | ) | |||
| Accounts payable | 47,703 | 98,885 | |||||
| Other | (18,372 | ) | (50,763 | ) | |||
| Net cash provided by operating activities | 371,295 | 267,547 | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
| Acquisition of property and equipment | (41,866 | ) | (35,358 | ) | |||
| Proceeds from sale of assets | 3,743 | 14,670 | |||||
| Business acquisitions, net of cash acquired | (12,494 | ) | (87,364 | ) | |||
| Other investing activities | (5,889 | ) | — | ||||
| Net cash used in investing activities | (56,506 | ) | (108,052 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
| Proceeds from warrant exercises | — | 20,916 | |||||
| Purchase of company stock | (250,261 | ) | — | ||||
| Other financing activities | (14,865 | ) | (5,648 | ) | |||
| Net cash (used in) provided by financing activities | (265,126 | ) | 15,268 | ||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 49,663 | 174,763 | |||||
| Cash and cash equivalents – beginning of the period | 294,186 | 119,423 | |||||
| CASH AND CASH EQUIVALENTS – END OF PERIOD | $ | 343,849 | $ | 294,186 | |||
Schedule 4
OPTION CARE HEALTH, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)
| Three Months Ended December 31, |
Year Ended December 31, |
||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net income | $ | 57,177 | $ | 47,529 | $ | 267,090 | $ | 150,556 | |||||||
| Interest expense, net | 12,432 | 14,798 | 51,248 | 53,806 | |||||||||||
| Income tax expense | 21,748 | 17,252 | 91,652 | 55,212 | |||||||||||
| Depreciation and amortization expense | 15,777 | 15,711 | 62,200 | 65,434 | |||||||||||
| EBITDA | 107,134 | 95,290 | 472,190 | 325,008 | |||||||||||
| EBITDA adjustments | |||||||||||||||
| Stock-based incentive compensation expense | 7,571 | 4,202 | 30,479 | 16,783 | |||||||||||
| Gain on sale of assets | — | (10,325 | ) | — | (10,325 | ) | |||||||||
| Restructuring, acquisition, integration and other (1) | (3,103 | ) | 5,105 | (77,486 | ) | 11,387 | |||||||||
| Adjusted EBITDA | $ | 111,602 | $ | 94,272 | $ | 425,183 | $ | 342,853 | |||||||
(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of merger-related expenses
